104 results
Page 5 of 6
8-K
EX-99.1
o4fnpqheip9ca5qr
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
jlpi2 twv
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
afwa4oxh4no1egpjciha
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
gwm6556ka9s
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
v1a85p3nut
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
gus40
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
iv6yk34wzchx240ornq1
4 Oct 19
Shelf registration
4:06pm
S-3
EX-1.2
iqyfkg2 8wo
4 Oct 19
Shelf registration
4:06pm
8-K
EX-99.1
tl5nwpvk4byiquev
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
8-K
EX-99.1
frnm8pjmk4s
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
8-K
27ghzmzum257gi kmhie
7 May 19
Other Events
12:00am
8-K
EX-99.1
99d3ai5dm6 77udv3qky
1 Apr 19
Sutro Biopharma Reports Full Year 2018 Financial Results
10:22am
10-K
xdhdwh3ozbq91
1 Apr 19
Annual report
12:00am
8-K
EX-99.1
sshnf24v
15 Nov 18
Sutro Biopharma Reports Third Quarter 2018 Financial Results
12:00am
10-Q
90qtj1zuod0lfsx
14 Nov 18
Quarterly report
12:00am